| Name | Title | Contact Details |
|---|
BioElectron is a platform biotechnology company, with expertise in the electron transfer (redox) chemical reactions that underpin oxidative stress and inflammation in all biological systems.
ChemNavigator is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Twist Bioscience is a synthetic biology company based in San Francisco, California. The company has developed a proprietary silicon-based manufacturing process for the production of synthetic DNA. Twist Bioscience serves Life Science researchers who are changing the world for the better. Coming from diverse fields of medicine, agriculture, industrial chemicals and data storage, scientists use our synthetic genes, oligo pools, and NGS target enrichment to better lives and improve the sustainability of the planet. Twist Bioscience is uniquely positioned to help accelerate these efforts by providing precision at a scale that is otherwise unavailable. Our technology overcomes inefficiencies and enables cost-effective, rapid, precise, high-throughput DNA synthesis and sequencing. We offer both the quality and quantity researchers need now to rapidly realize opportunities ahead.
A cancer diagnosis is something no one wants to hear. Today, it is often detected late, once it has spread and treatment options are often limited. But cancer is curable if caught in the earlier stages. At Thrive Earlier Detection, our goal is to transform this outlook: to catch cancer earlier, when it can be more effectively treated. We are developing CancerSEEK, a blood-based test that is designed to be affordable and utilized as part of routine medical care to detect multiple types of cancer at earlier stages. Our approach goes beyond a cancer diagnosis. We are developing a platform that will serve as a resource to help patients and their families maneuver the often confusing and overwhelming path that follows a cancer diagnosis.
NFlection is a biopharmaceutical company focused on the development of novel therapies to address the needs of patients with neurofibromatosis type 1, immunosuppressant-mediated squamous cell carcinoma, and congenital birthmarks such as keratinocytic epidermal nevi and nevus sebaceous.